skip nav
  Home | About CDC | Press Room | A-Z Index | Contact Us
spacer
CDC Centers for Disease Control and Prevention Home Page
CDC en Español
Search:  
CDC Home > HIV/AIDSTopics > Statistics and Surveillance > Reports > Selected Measures of Access to and Utilization of Treatment and Prophylaxis for HIV-Infected Persons
spacer
spacer spacer
spacer
 
Skip Nav spacer
spacer
Table 11. HIV-infected patients currently prescribed primary Pneumocystis carinii pneumonia (PCP) prophylaxis by data source and insurance status*
spacer
spacer
View PDF PDF icon

Data in Tables 11-13 are based on the following analyses:
  • In ASD (1999) and SHDC (1998), what proportion of eligible1 patients were prescribed primary prophylaxis for PCP?
Data Source Total   Private   Public   No Insurance
% Treated/
Eligible
% Treated/
Eligible
% Treated/
Eligible
% Treated/
Eligible
ASD 59 1,178/1,994   56 343/611   60 684/1,143   63 151/240
SHDC Site A 55 96/174 55 46/83 50 37/74 57 10/17
SHDC Site B 58 73/125 34 12/35 63 102/162 70 20/28
SHDC Site C 67 136/203 73 49/67 77 85/111 35 9/25
*Persons with unknown insurance status are not included.
  • Overall, between 55-67% of patients eligible to receive PCP prophylaxis were currently prescribed it.
  • Greater proportions of eligible patients were prescribed PCP prophylaxis at SHDC Site C compared with the other data sources.
  • For ASD and SHDC Site B, lesser proportions of patients with private insurance were prescribed PCP prophylaxis compared with patients with public insurance and with no insurance. ASD facilities include several large public hospitals and clinics that treat patients with HIV/AIDS, likely resulting in larger proportions of eligible patients with public insurance being prescribed PCP prophylaxis compared with patients with private insurance.
  • Similar proportions of patients with public insurance and no insurance were prescribed PCP prophylaxis in ASD and SHDC Site A. This may be due to the populations represented by the samples at the 3 SHDC sites (see Technical Notes). Sites A and B may contain more providers in and near metropolitan areas that routinely provide HIV-related care and may be more likely to prescribe prophylaxis regardless of the patient’s insurance status.
  • Data from the SHAS and MOPTB studies were not available for this question.
Last Modified: June 21, 2006
Last Reviewed: June 21, 2006
Content Source:
Divisions of HIV/AIDS Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
spacer
spacer
spacer
spacer
  Home | Policies and Regulations | Disclaimer | e-Government | FOIA | Contact Us
spacer
spacer
spacer Safer, Healthier People
spacer
Centers for Disease Control and Prevention, 1600 Clifton Rd, Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov.
spacer USA.gov: The U.S. Government's Official Web PortalDHHS Department of Health
and Human Services